Glenmark's Game-Changer: Generic Cure for Anaemia Hits US Market

Glenmark Pharmaceuticals is set to release a generic drug for anaemia in the US, aiming to mitigate side effects from high doses of medication. This move comes as Glenmark plans to distribute Leucovorin Calcium for Injection, with previous sales hitting USD 16.8 million. The stock saw a slight rise.

Glenmark Pharmaceuticals is set to shake up the US market by launching a generic medication aimed at treating anaemia and preventing severe side effects from medication overdoses. Scheduled for release this month, the product addresses concerns over high-dose medication limiting folic acid absorption.

The Mumbai-based pharmaceutical company is preparing to distribute Leucovorin Calcium for Injection USP in a 350 mg single-dose vial format through its US subsidiary. This launch follows considerable demand, as evidenced by the product's impressive USD 16.8 million annual sales recorded by IQVIA for the year ending October 2025.

The market has responded positively to these developments. Glenmark's shares experienced a 1.23% increase, hitting Rs 2,080.30 on the Bombay Stock Exchange. Industry experts are closely watching this release as a significant move in generic pharmaceuticals.

(With inputs from agencies.)